MS-N310 · Exercise and rehabilitation · Nutrition support · Survivorship · Human evidence · Appraised 12 November 2026

Does a 12-week multidisciplinary rehabilitation program improve recovery after upper gastrointestinal or hepatopancreaticobiliary cancer surgery?

Evidence at a glance

• Evidence label: Randomized controlled trial; modest improvement in cardiorespiratory fitness, without clear secondary-outcome benefit
• Benefit: Peak oxygen uptake improved by about 1.5 mL/kg/min after the program and remained about 1.23 mL/kg/min higher than standard care three months later.
• Certainty: Moderate for the measured fitness outcome; lower for broader function and quality of life because secondary endpoints did not differ.
• Risk: The abstract did not report adverse-event counts. The protocol required medical clearance, cardiopulmonary exercise testing, supervised sessions and weight monitoring.

What was studied

Regimen and population: RESTORE II randomized 88 disease-free survivors at least three months after resection for upper-GI or hepatopancreaticobiliary cancer (44 rehabilitation, 44 standard care). Median age was 67.5 years and median time since surgery was 33 months.

Program: Twelve weeks of physiotherapist-led aerobic and resistance exercise, one-to-one dietary counselling and psychosocial support. The primary endpoint was peak oxygen uptake; body composition, strength, performance, physical activity and EORTC quality of life were secondary.

What the evidence found

Relative to standard care, the adjusted mean increase in peak oxygen uptake was 1.50 mL/kg/min after treatment (95% CI 0.52–2.48; P=.003) and 1.23 mL/kg/min at three-month follow-up (95% CI 0.18–2.27; P=.02).

Body composition, grip and leg-press strength, short physical performance, measured activity and quality-of-life endpoints remained stable, with no significant between-group differences reported.

How to interpret it

The trial supports a structured rehabilitation pathway for improving a physiological fitness measure in selected postoperative survivors. The absolute improvement was modest and did not translate into demonstrated gains across the broader secondary endpoints.

Participants were disease-free survivors, not people receiving this program to control active cancer. The result does not establish reduced recurrence or improved survival.

Practical safety context

Post-upper-GI surgery care can involve weight loss, altered anatomy, dumping symptoms, pancreatic insufficiency or malabsorption. The protocol’s safeguards—medical clearance, exercise testing, supervised progression and close weight monitoring—matter.

Adverse-event counts and clinically important weight-loss outcomes were not verified from the accessible trial abstract; absence of reporting is not evidence of no harm.

Questions for the care team

• Has postoperative nutrition, weight trajectory and malabsorption been reviewed?
• Is formal exercise testing or physiotherapist supervision appropriate?
• What outcome matters most—fitness, daily function, symptoms or treatment recovery—and how will it be measured?

Funding and conflicts

The Health Research Board supported RESTORE II (DIFA-2018-009). Trial-level conflict details were not verified from the accessible abstract.

Sources

• RESTORE II randomized trial (PMID 42681576; DOI 10.1097/SLA.0000000000007189)
• ClinicalTrials.gov NCT03958019
• RESTORE II protocol and safety plan (PMCID PMC7222585)

Last literature search: 12 November 2026. Record appraisal: 12 November 2026. The primary trial abstract and the full protocol were appraised; unreported outcome and adverse-event details are marked as not verified. This page is educational and does not replace individualized medical advice. These supportive-care outcomes do not establish tumor shrinkage, delayed recurrence or longer survival.